A life sciences group that has developed a treatment to kill Covid with laser light will become the latest firm to list in London when it goes public today.
Ondine Biomedical will join the junior market in a £104m float. It hopes to raise around £23m to help roll out its first product.
Innovation: Ondine’s treatment destroys viruses – including Covid – bacteria, yeasts and fungi within minutes.
This is a treatment that destroys viruses – including Covid – bacteria, yeasts and fungi within minutes.
It works by a medical professional applying a ‘photodisinfection’ liquid into the nose – a key area for viruses to breed – and then illuminating it with a laser light, killing the pathogens in the process.
The Canadian company’s float comes as AIM has had its best year since 2006 – with more than 60 companies joining.
The technology Ondine uses was developed at Imperial College London and the group believes the stock market in the City has a better understanding of healthcare firms than Toronto.